Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2025-11-14 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于非独立董事辞职暨选举职工代表董事及补选董事会审计委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a non-independent director, the election of an employee representative director, and the supplementary election of an audit committee member. It includes details about the director's resignation, election process, qualifications, and related board resolutions. There are no financial statements, earnings data, or detailed financial analysis present. The document focuses on changes in the company's board and management structure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2025-11-14 Chinese
关于召开2025年第一次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the company's 2025 first extraordinary general meeting (临时股东大会). It includes information on the meeting date, voting methods (online and onsite), agenda items, registration procedures, and attachments such as proxy forms and voting instructions. There is no financial data, earnings information, or audit content. The document is not a report itself but a notice about the meeting and how shareholders can participate and vote. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document length is sufficient and contains detailed procedural information, confirming it is not a brief announcement or a simple report publication notice. Therefore, the correct classification is PSI with high confidence.
2025-11-11 Chinese
关于控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its controlling subsidiary obtaining a medical device registration certificate issued by a provincial drug regulatory authority. It includes details about the certificate, product, and potential impact on company performance. The document is short (890 characters) and does not contain financial statements, earnings data, or detailed management discussion. It is an official announcement about a regulatory approval related to product registration, not a financial report, management change, or shareholder meeting material. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-11-11 Chinese
对外投资管理制度(2025年10月）
Governance Information Classification · 95% confidence The document is titled '对外投资管理制度' which translates to 'External Investment Management System' and is issued by 美康生物科技股份有限公司. It is a detailed internal policy document outlining the company's procedures, decision-making authority, organizational responsibilities, and disclosure obligations related to external investments. The content includes governance rules, approval thresholds, reporting requirements, and internal controls for investments. It does not contain financial statements, earnings data, or audit results. It is not an announcement or a brief summary but a comprehensive internal management system document. This type of document fits best under Governance Information (CGR), as it details the company's internal rules and governance practices related to investment management.
2025-10-28 Chinese
董事会议事规则(2025年10月）
Governance Information Classification · 95% confidence The document is titled as "董事会议事规则" which translates to "Board Meeting Rules" or "Rules of Procedure for the Board of Directors". It details the composition, responsibilities, meeting procedures, voting rules, and record-keeping of the company's board of directors. There is no financial data, earnings information, or report publication mentioned. The content is focused on governance structure and internal rules for board operations. This matches the description of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices. The document length is sufficient and it is not a brief announcement or a certification. Therefore, the appropriate classification is CGR with high confidence.
2025-10-28 Chinese
对外报送信息管理制度（2025年10月）
Regulatory Filings Classification · 95% confidence The document is titled '对外报送信息管理制度' which translates to 'External Information Reporting Management System' and outlines the company's internal policies and procedures for managing the disclosure and reporting of information to external parties. It includes sections on confidentiality, approval processes, legal responsibilities, and attachments such as approval forms and confidentiality notices. There is no actual financial data, earnings, audit results, or report content presented. Instead, it is a governance or compliance document detailing how the company manages external information reporting to comply with laws and regulations. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a simple announcement or a voting result. The document is best classified under Regulatory Filings (RNS) as it is a compliance and procedural document related to regulatory requirements but does not itself constitute a financial or governance report.
2025-10-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.